Loading...
OTCM
DMPHF
Market cap2.16bUSD
, Last price  
Name

Dermapharm Holding SE

Chart & performance

D1W1MN
OTCM:DMPHF chart
P/E
—
P/S
—
EPS
2.67
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
7.97%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.16b
-1.34%
391,340,000384,843,000444,478,000467,117,000572,424,000700,879,000793,829,000942,912,0001,024,776,0001,135,351,0001,180,766,0001,164,978,000
Net income
132m
+16.37%
-61,00012,701,00016,824,00077,744,00075,323,00077,196,00085,826,000209,583,000134,236,00062,368,000113,787,000132,412,000
CFO
182m
-9.87%
54,256,00040,377,00076,778,00086,736,000159,128,000100,614,000131,098,000250,368,000288,533,000219,422,000201,378,000181,511,000
Dividend
Jun 29, 20261.0053 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

Related entities

Parent
Themis Beteiligungs-Aktiengesellschaft
Subsidiaries (5)
Allergopharma AG
Dermapharm AG
Dermapharm Aktiengesellschaft
mibe GmbH Arzneimittel
Strathmann GmbH & Co. KG

Key people

Wilhelm Beier
Chairman of the Supervisory Board · since 2017
Hans-Georg Feldmeier
Chairman of the Management Board, Chief Executive Officer · since 2017
Andreas Eberhorn
Chief Marketing Officer, Member of the Management Board · since 2022
Christof Dreibholz
Chief Financial Officer, Chief Compliance Officer, Member of the Management Board · since 2022
Erwin Kern
Independent Deputy Chairman of the Supervisory Board · since 2022
Independent Member of the Supervisory Board · since 2022
IPO date
Feb 09, 2018
Employees
3,404
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Lil-Dagover-Ring 7
Grünwald, BY 82031
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT